Endo acquires Indevus for up to $637 million
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticalsis to acquire Indevus Pharmaceuticalsfor around $370 million plus up to an additional $267 million in regulatory and sales milestone payments.